Stock listing

gettex:YB4P Savara, Inc. Aktie

German listing (gettex) of Savara, Inc. · home listing NASDAQ:SVRA

Follow Savara, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:SVRA

$4.26 USD -0.46 (-9.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SVRA

Past year -8.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.00 – $4.52 USDNov 20, 2026
Volume
17.01M sharesNov 20, 2026
Market cap
$939.9M USDAt the close on Nov 20, 2026 · price × 220.6M shares outstanding
52-week range
$4.00 – $7.01 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$12.85M USDMedian day 2.18M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Savara, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SVRA · Home$4.26 USD-0.46 (-9.7%)17,013,104$4.18$4.52$4.00$4.72Close on Nov 20, 2026
Frankfurt:YB4P€3.917 EUR-0.583 (-13.0%)—€4.666€4.666€3.917€4.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SVRA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.26-0.46-9.7%$4.18$4.52$4.0017,013,104
$4.72+0.24+5.4%$4.60$4.87$4.555,510,085
$4.48+0.015+0.3%$4.60$4.60$4.353,790,035
$4.465-0.175-3.8%$4.70$4.735$4.402,769,865
$4.64-0.08-1.7%$4.80$4.84$4.583,229,455
$4.72-0.27-5.4%$5.03$5.03$4.674,292,661
$4.99+0.07+1.4%$4.99$5.205$4.929,260,244
$4.92-0.13-2.6%$4.86$5.15$4.841,728,042
$5.05+0.22+4.6%$4.943$5.065$4.762,399,378
$4.83+0.45+10.3%$4.46$4.89$4.412,216,685
$4.38-0.28-6.0%$4.63$4.636$4.3252,891,977
$4.66-0.09-1.9%$4.84$4.88$4.463,559,075
$4.75+0.02+0.4%$4.78$4.88$4.6552,110,362
$4.73-0.09-1.9%$4.83$4.91$4.671,775,756
$4.82-0.13-2.6%$4.936$4.97$4.751,409,437
$4.95-0.07-1.4%$5.05$5.13$4.9151,740,801
$5.02+0.16+3.3%$4.82$5.05$4.7751,785,855
$4.86+0.34+7.5%$4.49$4.905$4.453,590,010
$4.52+0.30+7.1%$4.30$4.535$4.2163,441,276
$4.22-0.32-7.0%$4.52$4.58$4.132,827,900
$4.54-0.13-2.8%$4.65$4.75$4.452,709,700
$4.67-0.09-1.9%$4.79$4.945$4.662,086,100
$4.76+0.13+2.8%$4.64$4.99$4.604,417,400
$4.63+0.18+4.0%$4.53$4.705$4.4951,560,300
$4.45-0.29-6.1%$4.75$4.77$4.442,235,000
$4.74-0.02-0.4%$4.76$4.90$4.721,690,900
$4.76-0.02-0.4%$4.71$4.82$4.652,574,300
$4.78-0.06-1.2%$4.84$5.02$4.763,742,100
$4.84-0.08-1.6%$4.93$5.00$4.811,306,700
$4.92+0.09+1.9%$4.82$4.975$4.811,529,100
$4.83-0.05-1.0%$4.85$4.92$4.6352,514,600
$4.88+0.23+4.9%$4.74$5.05$4.692,414,900
$4.65-0.13-2.7%$4.82$4.84$4.602,289,400
$4.78-0.03-0.6%$4.85$4.915$4.712,862,300
$4.81-0.235-4.7%$5.10$5.16$4.7652,653,300
$5.045-0.115-2.2%$5.15$5.24$5.032,549,600
$5.16+0.08+1.6%$5.15$5.24$5.056,051,300
$5.08+0.01+0.2%$5.07$5.19$5.002,034,700
$5.07+0.07+1.4%$4.97$5.155$4.864,371,000
$5.00-0.07-1.4%$5.08$5.18$4.872,451,000
$5.07+0.07+1.4%$5.03$5.085$4.8842,499,200
$5.00-0.30-5.7%$5.30$5.34$4.903,352,900
$5.30-0.15-2.8%$5.52$5.525$5.291,412,900
$5.45+0.08+1.5%$5.44$5.51$5.361,311,900
$5.37-0.05-0.9%$5.42$5.47$5.3052,181,900
$5.42+0.29+5.7%$5.23$5.465$5.221,228,700
$5.13-0.13-2.5%$5.29$5.351$5.1051,127,000
$5.26-0.08-1.5%$5.33$5.34$5.1751,301,400
$5.34+0.04+0.8%$5.33$5.43$5.281,310,100
$5.30-0.02-0.4%$5.38$5.395$5.271,063,700
$5.32-0.095-1.8%$5.34$5.46$5.241,525,400
$5.415-0.115-2.1%$5.48$5.57$5.371,095,500
$5.53+0.16+3.0%$5.27$5.63$5.261,660,800
$5.370.000.0%$5.32$5.39$5.31625,200
$5.37-0.09-1.6%$5.52$5.52$5.291,240,400
$5.46+0.11+2.1%$5.47$5.56$5.3651,216,800
$5.35-0.04-0.7%$5.32$5.405$5.291,042,100
$5.39+0.13+2.5%$5.25$5.44$5.211,958,700
$5.26-0.23-4.2%$5.48$5.51$5.251,336,300
$5.49-0.12-2.1%$5.59$5.66$5.4851,595,300
$5.61+0.01+0.2%$5.58$5.68$5.511,529,800
$5.60+0.04+0.7%$5.69$5.72$5.521,608,654
$5.56-0.03-0.5%$5.60$5.60$5.4251,323,851
$5.59+0.10+1.8%$5.54$5.64$5.503,035,200
$5.49-0.09-1.6%$5.52$5.59$5.262,541,800

Splits

3 splits since 2000 · NASDAQ:SVRA · every price before a split is adjusted for it

DayRatioWhat
1-for-70Consolidation
1-for-25Consolidation
1-for-1.99Consolidation
Ticker
gettex:YB4P
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Savara, Inc. news

Savara, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 158 in all · newest Nov 20, 2026 · oldest 2019
Decks
66 decks · latest Sep 6, 2026

Where Savara, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SVRA · Home listingNASDAQUnited StatesUSD
Lang & Schwarz:A2DQ2BLang & SchwarzGermanyEUR
LS Exchange:A2DQ2BLS ExchangeGermanyEUR
gettex:YB4P · This pagegettexGermanyEUR
Frankfurt:YB4PFrankfurtGermanyEUR
BOATS:SVRABOATSUnited StatesUSD
Tradegate:YB4PTradegateGermanyEUR
Dusseldorf:YB4PDusseldorfGermanyEUR
Munich:YB4PMunichGermanyEUR
Stuttgart:YB4PStuttgartGermanyEUR

Valuation

Price/book 8.7× against a median of 2.4×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$840.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
8.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.3×
Beta vs S&P 500
1.42

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Savara, Inc. · NASDAQ:SVRAUS$939.9MUS$840.4Mn/an/an/a8.7×n/a0.3×1.42
Omeros Corporation · NASDAQ:OMERUS$983.7MUS$920.3M10.0×12.4×n/an/a132.3%n/a1.64
Everest Medicines Ltd. · HKEX:1952US$981.6MUS$1.00Bn/a2.8×183×1.3×−2.2%0.4×n/a
HBM Holdings Ltd. · HKEX:2142US$981.4MUS$711.6M10.7×4.5×8.6×2.4×57.8%0.2×n/a
Peptron, Inc. · KRX:087010US$979.2MUS$942.2Mn/a211×n/a10.2×−342.2%0.2×n/a
City Therapeutics, Inc. · NASDAQ:CTYUS$972.4MUS$802.8Mn/a59.2×n/an/a−431.4%n/an/a
Seaport Therapeutics, Inc. · NASDAQ:SPTXUS$966.2MUS$675.8Mn/an/an/a2.4×n/a0.0×0.72
MoonLake Immunotherapeutics · NASDAQ:MLTXUS$942.1MUS$543.7Mn/an/an/a2.5×n/a0.3×1.32
Metis TechBio Co., Ltd. Class H · HKEX:7666US$918.2MUS$486.7Mn/a222×n/a2.0×−373.2%0.0×n/a
InventisBio, Co., Ltd. Class A · SSE:688382US$899.5MUS$714.3Mn/a67.0×n/a4.6×−533.7%0.0×n/a
InnoCare Pharma Ltd. Class A · SSE:688428US$896.7M−US$209.5M9.3×−0.6×−2.3×0.8×27.1%0.1×n/a
Median of the othersUS$969.3MUS$712.9M10.0×35.8×8.6×2.4×−172.2%0.2×1.32

Forecasts

6 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
11.06 USD · Analysts' mean
EPS, year to Dec 2026
-0.62 · 5 analysts
Revenue, year to Dec 2026
880K · 6 analysts

Team and board

Officers

OfficerRole
Matt PaulsChair of the Board of Directors, Chief Executive Officer
Rob LutzChief Operating and Financial Officer
Kate McCabeChief Legal Officer
Brian RobinsonEVP, Global Medical Affairs
Charles LaPreeEVP, Head of Global Regulatory Affairs
Sid AdvantEVP, Global Technical Operations
Anne EricksonChief Business and Corporate Affairs Officer
Braden ParkerChief Commercial Officer
Megan CarpenterChief People Officer
Yasmine WasfiChief Medical Officer

Board

DirectorRole
Matt PaulsChair of the Board of Directors, Chief Executive Officer
Ali AtayaM.D., MBA, ATSF
An van Es-JohanssonAudit Committee, Compensation Committee
Bruce TrapnellM.D.
Cormac McCarthyM.D., Ph.D., FRCPI
David A. RamsayAudit Committee (Chair), Nominating & Governance Committee
Francesco BonellaM.D., Ph.D
Ilaria CampoPh.D.
Joe McCrackenNominating & Governance Committee (Chair), Compensation Committee
Maria KokosiM.D.
Nevan ElamCompensation Committee (Chair), Nominating & Governance Committee
Richard J. HawkinsAudit Committee
Yoshikazu InoueM.D., Ph.D.

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−2.6%
Q2 2026Aug 11, 2026 · After close+2.3%
Q1 2026May 7, 2026−0.8%
Q4 2025Mar 13, 2026 · Before open−1.3%
Q3 2025Nov 12, 2025 · After close+3.4%
Q2 2025Aug 13, 2025 · Before open+4.7%
Q1 2025May 7, 2025 · Before open+2.0%
Q4 2024Mar 27, 2025 · Before open+3.0%
Q3 2024Nov 12, 2024 · Before open−5.9%
Q2 2024Aug 12, 2024 · After close+1.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close−8.2%
Q4 2023Mar 7, 2024 · After close−5.2%
Q3 2023Nov 9, 2023 · After close+1.8%
Q2 2023Aug 10, 2023 · After close+1.0%
Q1 2023May 15, 2023 · Before open−0.5%
Q4 2022Mar 30, 2023 · After close−4.4%
Q3 2022Nov 10, 2022 · After close+2.6%
Q2 2022Aug 11, 2022 · After close+0.6%
Q1 2022May 11, 2022 · After close+1.8%
Q4 2021Mar 30, 2022 · After close+3.1%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2026)Technical11 slidesSep 6, 2026
American Thoracic Society (ATS) 2026 International ConferenceConference9 slidesMay 18, 2026
Investor Presentation (January 2026)Investor deck47 slidesJan 9, 2026
Investor Presentation (October 2025)Investor deck15 slidesOct 29, 2025
Investor Presentation (September 2025)Investor deck48 slidesSep 2, 2025
Investor Presentation (May 2025)Investor deck47 slidesMay 2025
Investor Presentation (March 2025)Investor deck47 slidesMarch 2025
Investor Presentation (January 2025)Investor deck43 slidesJanuary 2025
Investor Presentation (December 2024)Investor deck34 slidesDec 20, 2024
Technical Presentation (2024)Technical15 slidesDec 5, 2024
Show 50 decks
DeckKindSlidesDate
Investor Presentation (November 2024)Investor deck34 slidesNovember 2024
Investor Presentation (October 2024)Investor deck34 slidesOctober 2024
Investor Presentation (September 2024)Investor deck33 slidesSeptember 2024
Investor Presentation (September 2024)Investor deck34 slidesSeptember 2024
Investor Presentation (July 2024)Investor deck33 slidesJuly 2024
Investor Presentation (July 2024)Investor deck33 slidesJuly 2024
Investor Presentation (May 2024)Investor deck32 slidesMay 2024
Investor Presentation (April 2024)Investor deck32 slidesApr 25, 2024
Investor Presentation (February 2024)Investor deck32 slidesFeb 22, 2024
J.P. Morgan Healthcare Conference 2024Conference32 slidesJanuary 2024
Investor Presentation (November 2023)Investor deck31 slidesNovember 2023
Investor Presentation (October 2023)Investor deck31 slidesOctober 2023
Investor Presentation (August 2023)Investor deck31 slidesAugust 2023
Investor Presentation (June 2023)Investor deck32 slidesJune 2023
Investor Presentation (June 2023)Investor deck32 slidesJune 2023
Investor Presentation (June 2023)Investor deck31 slidesJune 2023
Investor Presentation (May 2023)Investor deck29 slidesMay 2023
Investor Presentation (February 2023)Investor deck29 slidesFebruary 2023
Investor Presentation (December 2022)Investor deck29 slidesDecember 2022
Investor Presentation (September 2022)Investor deck30 slidesSeptember 2022
Investor Presentation (August 2022)Investor deck30 slidesAugust 2022
Investor Presentation (July 2022)Investor deck30 slidesJuly 2022
Investor Presentation (June 2022)Investor deck30 slidesJune 2022
Investor Presentation (May 2022)Investor deck30 slidesMay 2022
Investor Presentation (March 2022)Investor deck30 slidesMarch 2022
Investor Presentation (January 2022)Investor deck30 slidesJanuary 2022
Investor Presentation (March 2021)Investor deck18 slidesMar 16, 2021
Investor Presentation (January 2021)Investor deck17 slidesJan 19, 2021
Technical Presentation (October 2019)Technical25 slidesOct 2, 2019
Investor Presentation (February 2018)Investor deck24 slidesFeb 12, 2018
Investor Presentation (June 2017)Investor deck22 slidesJune 2017
Mast Therapeutics — Investor Presentation (April 2017)Investor deck24 slidesApr 24, 2017
Mast Therapeutics — Merger or Acquisition (March 2017)Merger or acquisition26 slidesMar 6, 2017
Mast Therapeutics — Merger or Acquisition (January 2017)Merger or acquisition21 slidesJan 9, 2017
Mast Therapeutics — Investor Presentation (October 2016)Investor deck21 slidesOct 19, 2016
Mast Therapeutics — Investor Presentation (September 2016)Investor deck45 slidesSep 7, 2016
Mast Therapeutics — Investor Presentation (August 2016)Investor deck45 slidesAug 10, 2016
Mast Therapeutics — Investor Presentation (March 2016)Investor deck48 slidesMar 7, 2016
Mast Therapeutics — Investor Presentation (January 2016)Investor deck44 slidesJan 11, 2016
Mast Therapeutics — Investor Day (October 2015)Investor day70 slidesOct 7, 2015

This page holds 50 of 66 decks. Open Decks

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$149.5M raised
Use of proceeds: Accelerate investment in preparing for potential commercialization of MOLBREEVI
Nov 12, 2025
Royalty on U.S. net sales of MOLBREEVI
Announced: US$75M
Buyers: RTW ($75 million royalty funding; tiered single digit percentage of annual U.S. net sales of MOLBREEVI, subject to a cap)
Use of proceeds: Support the potential U.S. launch and commercialization of MOLBREEVI in autoimmune PAP
Oct 29, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00001.00K257.0K000400.0K
Cost of revenue245.0K78.0M44.3M27.9M29.0M35.0M38.8M526.0K363.0K8.18M
Gross profit-245.0K-78.0M-44.3M-27.9M-29.0M-34.8M-38.8M-526.0K-363.0K400.0K
Research and development81.4M78.0M44.3M27.9M29.0M35.0M38.8M37.2M18.5M8.18M
Selling, general and administrative42.1M25.0M15.7M10.9M12.3M12.0M12.9M10.7M11.1M9.34M
Operating income-123.5M-103.2M-60.0M-38.8M-41.5M-49.3M-79.0M-70.0M-30.0M-10.9M
Depreciation and amortization87.0K130.0K77.0K31.0K136.0K255.0K1.01M526.0K363.0K99.0K
EBITDA-123.5M-103.1M-59.9M-38.8M-41.3M-49.0M-78.0M-69.5M-29.6M-10.8M
Interest expense88.0K2.28M1.48M70.0K11.0K1.16M452.0K
Income before tax-118.8M-95.9M-54.7M-38.1M-43.0M-49.6M-78.2M-68.6M-33.4M-11.3M
Income tax09.00K797.0K796.0K2.28M1.48M26.9M-7.06M-3.63M-357.0K
Net income-118.8M-95.9M-54.7M-38.1M-43.0M-49.6M-78.2M-61.5M-29.8M-10.9M
Earnings per share, basic-0.53-0.48-0.33-0.25-0.32-0.84-1.95-1.85-1.76-5.62
Earnings per share, diluted-0.53-0.48-0.33-0.25-0.32-0.84-1.95-1.85-1.76-5.62

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents33.2M15.1M26.6M52.1M34.0M22.9M49.8M24.3M22.1M13.4M
Short-term investments202.5M181.2M135.7M73.8M127.2M59.3M72.0M86.5M72.2M0
Receivables1.25M1.04M1.00M954.0K1.14M1.70M1.62M1.68M1.03M868.0K
Inventory12.05M-1.14M-1.70M-1.62M2.48M337.0K
Current assets241.6M202.1M165.9M129.0M165.0M85.1M124.1M113.3M97.9M14.6M
Property, plant and equipment100.0K165.0K270.0K51.0K73.0K156.0K352.0K522.0K925.0K793.0K
Goodwill0026.9M27.1M3.05M
Total assets253.4M212.9M177.6M139.8M176.6M97.7M136.2M152.3M159.6M28.9M
Accounts payable5.76M4.54M3.50M1.33M1.44M2.60M3.41M3.88M2.78M536.0K
Current liabilities20.4M14.7M10.6M5.87M14.7M8.17M10.9M7.25M6.01M3.46M
Long-term debt29.9M26.6M26.3M26.1M17.3M25.1M23.1M24.5M14.8M2.29M
Total debt29.9M26.6M26.3M26.1M25.7M25.1M25.6M24.6M15.3M4.47M
Total liabilities50.3M41.4M37.2M32.0M32.1M33.4M34.5M44.1M40.3M20.9M
Shareholders' equity203.1M171.4M140.4M107.8M144.5M64.4M101.7M108.2M119.3M-35.9M
Shares outstanding204.6M172.4M138.1M114.0M114.0M54.2M50.8M35.1M30.5M3.16M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-101.0M-89.1M-51.1M-34.6M-40.1M-39.8M-45.1M-39.3M-28.2M-8.37M
Capital spending-22.0K-25.0K-296.0K-9.00K-57.0K-47.0K-148.0K-141.0K-495.0K-8.00K
Free cash flow-101.1M-89.1M-51.4M-34.6M-40.1M-39.9M-45.3M-39.4M-28.7M-8.38M
Cash from investing-18.4M-39.9M-57.1M52.6M-69.5M9.05M15.7M-13.6M-69.1M-8.00K
Cash from financing137.8M117.6M82.8M87.0K120.8M3.69M54.9M55.2M106.1M5.12M
Dividends paid-2.12M00
Share buybacks-5.14M-995.0K-1.21M-3.00K-78.0K2.12M54.9M46.4M91.3M19.3M
Change in cash18.1M-11.5M-25.5M18.1M11.1M-26.9M25.5M2.18M8.75M-3.31M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 11, 2026Offer documentSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
4 · Change in ownershipJul 24, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
8-K · Current reportJun 8, 2026Management or board changeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
8-K · Current reportMar 13, 2026Material contractSEC
10-K · Annual reportMar 13, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
8-K · Current reportJan 27, 2026Material contractSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
8-K · Current reportJan 9, 2026Current reportSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 18, 2025Other filingsSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2025Big-stake noticeSEC
424B5 · ProspectusOct 30, 2025Offer documentSEC
8-K · Current reportOct 30, 2025Material contractSEC
424B5 · ProspectusOct 29, 2025Offer documentSEC
8-K · Current reportOct 29, 2025Material contractSEC
4 · Change in ownershipOct 22, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
8-K · Current reportSep 2, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 8, 2025Big-stake noticeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
8-K · Current reportJun 6, 2025Meeting outcomeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 27, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
10-K/A · Annual report, amendedApr 25, 2025Annual reportSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
8-K · Current reportMar 31, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 27, 2025Big-stake noticeSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 26, 2025Material contractSEC
3 · Initial statement of ownershipMar 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 10, 2025Big-stake noticeSEC
8-K · Current reportJan 23, 2025Management or board changeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
SC 13G · Big-stake noticeNov 27, 2024Big-stake noticeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
S-8 · Registration statement for employee plansOct 1, 2024Offer documentSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 27, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansJul 26, 2024Offer documentSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 8, 2024Big-stake noticeSEC
8-K · Current reportJun 28, 2024Material contractSEC
424B5 · ProspectusJun 28, 2024Offer documentSEC
8-K · Current reportJun 26, 2024Current reportSEC
8-K/A · Current report, amendedJun 10, 2024Management or board changeSEC
8-K · Current reportJun 7, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 22, 2024Other filingsSEC
CORRESP · Letter to the SECMay 20, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2024Other filingsSEC
S-3 · Registration statementMay 9, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedApr 12, 2024Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 12, 2024Meeting noticeSEC
8-K · Current reportApr 12, 2024Material contractSEC
3 · Initial statement of ownershipMar 29, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 7, 2024Offer documentSEC
10-K · Annual reportMar 7, 2024Annual reportSEC
8-K · Current reportFeb 16, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 1, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 31, 2024Big-stake noticeSEC
8-K · Current reportJan 25, 2024Management or board changeSEC
8-K · Current reportJan 5, 2024Current reportSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
144 · Notice of proposed saleDec 28, 2023Other filingsSEC
144 · Notice of proposed saleDec 28, 2023Other filingsSEC
144 · Notice of proposed saleDec 28, 2023Other filingsSEC
4 · Change in ownershipDec 18, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedJul 26, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeJul 25, 2023Big-stake noticeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
4 · Change in ownershipJul 19, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJul 19, 2023Big-stake noticeSEC
8-K · Current reportJul 13, 2023Material contractSEC
424B5 · ProspectusJul 13, 2023Offer documentSEC
4 · Change in ownershipJun 27, 2023Insider tradeSEC
S-8 · Registration statement for employee plansJun 16, 2023Offer documentSEC
8-K · Current reportJun 9, 2023Meeting outcomeSEC
8-K · Current reportJun 8, 2023Current reportSEC
4 · Change in ownershipMay 26, 2023Insider tradeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportMar 30, 2023Current reportSEC
S-8 · Registration statement for employee plansMar 30, 2023Offer documentSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 10, 2023Current reportSEC
8-K · Current reportMar 2, 2023Material contractSEC
4 · Change in ownershipFeb 28, 2023Insider tradeSEC
3 · Initial statement of ownershipFeb 22, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
8-K · Current reportFeb 14, 2023Management or board changeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Savara, Inc.’s releases · as of Nov 10, 2026

Common shares
220,623,511
Fully diluted
220,690,511

Fully diluted

LineSharesAs of
Common shares220,623,511Nov 9, 2026
Options and RSUs67,000Nov 10, 2026

Warrants and options

Lot
Stock options · US$4.92 · expire about Nov 2036
RSUs · expiry not stated
PSUs · expiry not stated

Share count over time

CountShares
Nov 9, 2026220,623,511

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
NEA Management Company, LLC24.5MUS$126MSep 30, 2026
Venrock Adviser, LLC19.6MUS$101MSep 30, 2026
Bain Capital Life Sciences Investors, LLC17.6MUS$90.8MSep 30, 2026
Deerfield Management Company, L.P.13.6MUS$70MSep 30, 2026
BlackRock12.6MUS$65MSep 30, 2026
TCG Crossover Management, LLC12.4MUS$63.8MSep 30, 2026
Polar Capital Holdings Plc11.5MUS$59.1MSep 30, 2026
Vanguard10.9MUS$56.5MSep 30, 2026
Nantahala Capital Management, LLC7.14MUS$36.8MSep 30, 2026
State Street6.64MUS$34.3MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Marshall Wace, LLP6.39MUS$33MSep 30, 2026
Rtw Investments, LP5.95MUS$30.7MSep 30, 2026
Spruce Street Capital LP5.38MUS$27.8MSep 30, 2026
Geode Capital4.13MUS$21.3MSep 30, 2026
Orbimed Advisors LLC3.96MUS$20.4MSep 30, 2026
Woodline Partners LP3.91MUS$20.2MSep 30, 2026
Wellington3.35MUS$17.3MSep 30, 2026
Vestal Point Capital, LP3.3MUS$17MSep 30, 2026
Rosalind Advisors, Inc.3.18MUS$16.4MSep 30, 2026
Emerald Advisers, LLC3.14MUS$16.2MSep 30, 2026
Pictet Asset Management Holding SA2.68MUS$13.8MSep 30, 2026
Affinity Asset Advisors, LLC2.51MUS$13MSep 30, 2026
D. E. Shaw & Co., Inc.2.4MUS$12.4MSep 30, 2026
Emerald Mutual Fund Advisers Trust2.4MUS$12.4MSep 30, 2026
Nan Fung Trinity (Hk) LTD1.84MUS$9.51MSep 30, 2026
Silverarc Capital Management, LLC1.52MUS$7.84MSep 30, 2026
ADAR1 Capital Management, LLC1.41MUS$7.28MSep 30, 2026
Schwab1.34MUS$6.93MSep 30, 2026
Northern Trust1.33MUS$6.85MSep 30, 2026
Algert Global LLC1.17MUS$6.02MSep 30, 2026
Frazier Life Sciences Management, L.P.1.11MUS$5.75MSep 30, 2026
Longaeva Partners L.P.1.11MUS$5.73MSep 30, 2026
BNP Paribas1.08MUS$5.57MSep 30, 2026
Superstring Capital Management LP1.02MUS$5.25MSep 30, 2026
DWS860KUS$4.44MSep 30, 2026
UBS841KUS$4.34MSep 30, 2026
Hrt Financial LP832KUS$4.29MSep 30, 2026
Ameriprise825KUS$4.26MSep 30, 2026
Sphera Funds Management LTD.803KUS$4.14MSep 30, 2026
Swedbank AB786KUS$4.06MSep 30, 2026
Goldman Sachs741KUS$3.82MSep 30, 2026
F/m Investments LLC678KUS$3.5MSep 30, 2026
Squadron Capital Management LLC675KUS$3.48MSep 30, 2026
DCF Advisers, LLC670KUS$3.46MSep 30, 2026
Sio Capital Management, LLC657KUS$3.39MSep 30, 2026
Voya Investment Management LLC634KUS$3.27MSep 30, 2026
Susquehanna625KUS$3.22MSep 30, 2026
KVP Capital Advisors, LP605KUS$3.12MSep 30, 2026
Integral Health Asset Management, LLC600KUS$3.1MSep 30, 2026
Y-Intercept (Hong Kong) Ltd565KUS$2.92MSep 30, 2026

This page holds 50 of 174 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund6.16MUS$38MJun 30, 2026
iShares Russell 2000 ETF4MUS$24.7MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF3.2MUS$19.7MJun 30, 2026
Fidelity Small Cap Index Fund1.67MUS$9.13MJul 31, 2026
Vanguard Extended Market Index Fund1.56MUS$9.58MJun 30, 2026
iShares Russell 2000 Growth ETF1.44MUS$8.85MJun 30, 2026
SmallCap Growth Fund I932KUS$5.09MJul 31, 2026
Emerald Growth Fund799KUS$4.19MApr 30, 2026
Emerald Growth Fund799KUS$4.36MJul 31, 2026
Vanguard Russell 2000 Index Fund753KUS$3.91MMay 31, 2026
Show 50 holders
HolderSharesValueAs of
iShares Biotechnology ETF752KUS$4.63MJun 30, 2026
Fidelity Extended Market Index Fund705KUS$3.66MMay 31, 2026
F/m Emerald Life Sciences Innovation ETF651KUS$3.39MMay 31, 2026
Schwab U.S. Small-Cap ETF647KUS$3.36MMay 31, 2026
iShares Micro-Cap ETF512KUS$3.15MJun 30, 2026
North Square Dynamic Small Cap Fund431KUS$2.24MMay 31, 2026
Janus Henderson Small Cap Growth Alpha ETF409KUS$2.24MJul 31, 2026
Schwab Small-Cap Index Fund371KUS$2.03MJul 31, 2026
Vanguard U.S. Momentum Factor ETF302KUS$1.57MMay 31, 2026
Master Small Cap Index Series286KUS$1.76MJun 30, 2026
Fidelity Total Market Index Fund266KUS$1.38MMay 31, 2026
Voya Small Company Portfolio245KUS$1.51MJun 30, 2026
Voya MI Dynamic Small Cap Fund220KUS$1.15MMay 31, 2026
Small Cap Equity Fund209KUS$1.29MJun 30, 2026
Fidelity Series Total Market Index Fund209KUS$1.08MMay 31, 2026
Vanguard Health Care Index Fund206KUS$1.07MMay 31, 2026
Nuveen Small Cap Blend Index Fund203KUS$1.11MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF170KUS$1.04MJun 30, 2026
EQ/2000 Managed Volatility Portfolio167KUS$1.03MJun 30, 2026
Fidelity Small Cap Growth Index Fund143KUS$883KJun 30, 2026
Vanguard Russell 2000 Growth Index Fund137KUS$711KMay 31, 2026
Fidelity Nasdaq Composite Index Fund122KUS$635KMay 31, 2026
LVIP State Street Small-Cap Index Fund109KUS$672KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares109KUS$593KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF106KUS$577KJul 31, 2026
Vanguard Balanced Index Fund105KUS$647KJun 30, 2026
Fidelity Enhanced Small Cap Core ETF104KUS$640KJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund94,779US$584KJun 30, 2026
Nuveen Equity Index Fund84,078US$459KJul 31, 2026
Optimize Strategy Index ETF83,811US$516KJun 30, 2026
Fidelity Nasdaq Composite Index ETF80,699US$420KMay 31, 2026
Schwab U.S. Broad Market ETF80,211US$417KMay 31, 2026
Schwab Total Stock Market Index Fund79,785US$436KJul 31, 2026
Small Cap Index Fund78,682US$485KJun 30, 2026
Global X Russell 2000 ETF73,241US$400KJul 31, 2026
Fidelity ZERO Total Market Index Fund72,886US$398KJul 31, 2026
EQ/Small Company Index Portfolio67,280US$414KJun 30, 2026
Small Cap Index Fund60,602US$315KMay 31, 2026
VIP Disciplined Small Cap Portfolio59,279US$365KJun 30, 2026
Virtus Biotech Clinical Trials Etf59,090US$323KJul 31, 2026

This page holds 50 of 129 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Lowrance David L
Officer: Chief Financial Officer
Sale394,528USD 5.68US$2.24MJun 22, 2026

Big stakes

StakeStakeSharesDateFiling
Growth Equity Opportunities 17, LLC12.00%24.5MNov 12, 2025Schedule 13D
Bain Capital Life Sciences Fund II, L.P.9.99%17.6MMar 25, 2025Schedule 13D
Venrock Healthcare Capital Partners III, L.P.9.90%20.9MDec 31, 2025Schedule 13G
Farallon Capital Management, L.L.C.6.80%15MJun 30, 2026Schedule 13G
Deerfield Mgmt, L.P.6.74%13.6MOct 30, 2025Schedule 13G
TCG Crossover GP I, LLC6.10%12.4MDec 31, 2025Schedule 13G
Polar Capital Holdings Plc5.58%11.5MSep 30, 2026Schedule 13G
BlackRock, Inc.5.40%11MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ted W Love
Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past)
Director · Sep 5, 2012 – Jun 19, 2013 · Past
Alexander J Denner
Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Nov 9, 2020); Bioverativ Inc (Director · Jan 10, 2017 – Mar 8, 2018 · Past); The Medicines Company (Director · Feb 2, 2016 – Jan 6, 2020 · Past); Ariad Pharmaceuticals Inc (Director · Feb 20, 2014 – Feb 16, 2017 · Past); VIVUS Inc (Director · Aug 14, 2013 – Oct 30, 2015 · Past); Biogen Inc. (Director · Jun 10, 2009 – Jun 15, 2022 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Aug 8, 2012 · Past); Viskase Holdings, Inc. (Director · May 21, 2009 – Jan 2, 2013 · Past)
Director · Oct 26, 2006 – Oct 16, 2009 · Past
Matt Pauls
Other companies: Palvella Therapeutics, Inc. (Director · Since at least Jun 29, 2026); Pelthos Therapeutics Inc. (Director · Since at least Jul 1, 2025); Soleno Therapeutics, Inc. (Director · Since at least Aug 15, 2023); Egalet Corporation (Director · Jan 31, 2019 – May 20, 2020 · Past); Strongbridge Biopharma plc (President & CEO, Director · Jan 1, 2018 – Feb 20, 2019 · Past)
CHIEF EXECUTIVE OFFICER, Director · Since at least Oct 29, 2015
Brandi Roberts
Other companies: Definium Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 2, 2025); TFF Pharmaceuticals Inc (Director · Mar 25, 2022 – Jul 3, 2024 · Past); Longboard Pharmaceuticals Inc (Executive VP and CFO · Mar 11, 2021 – Dec 2, 2024 · Past); Lineage Cell Therapeutics, Inc. (CFO & SVP Finance · Jan 7, 2019 – Mar 17, 2020 · Past)
Chief Financial Officer & SVP · Jun 19, 2013 – Jan 20, 2017 · Past
Santosh Vetticaden
Other companies: Depomed Inc (SVP, Chief Medical Officer *** · Oct 16, 2017 – Feb 6, 2018 · Past); INSYS Therapeutics Inc (Interim CEO and CMO · Jan 9, 2017 – Feb 21, 2017 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Medical Officer · Dec 2, 2008 – Dec 30, 2011 · Past); Maxygen Inc (Chief Medical Officer · Feb 13, 2007 – Jul 1, 2008 · Past)
Chief Medical Officer & SVP · Sep 5, 2012 – Jun 19, 2014 · Past
Joe McCracken
Other companies: Lumos Pharma Inc (Director · Mar 23, 2020 – Dec 12, 2024 · Past); Kindred Biosciences Inc (Director · Apr 20, 2018 – Aug 27, 2021 · Past); Nexvet Biopharma plc (Director · Feb 4, 2015 – Jul 31, 2017 · Past)
Nominating & Governance Committee (Chair), Compensation Committee · Since at least Apr 27, 2017
Michael M Goldberg
Other companies: Echo Therapeutics Inc (Director · Feb 28, 2014 – Mar 21, 2017 · Past); Urigen Pharmaceuticals Inc (Director · Jun 11, 2009 – Aug 13, 2009 · Past); Emisphere Technologies Inc (Director · Dec 19, 2006 – Aug 22, 2007 · Past)
Director · Jun 2, 2006 – Jun 30, 2010 · Past
Richard J. Hawkins
Other companies: Plus Therapeutics, Inc. (Director · Since at least Jun 25, 2020); Lumos Pharma Inc (Chief Executive Officer, Director · Mar 18, 2020 – Dec 12, 2024 · Past); SciClone Pharmaceuticals Inc (Director · Oct 13, 2017 – Oct 13, 2017 · Past)
Audit Committee · Since at least Dec 17, 2017
An van Es-Johansson
Other companies: Plus Therapeutics, Inc. (Director · Since at least Jan 1, 2020); Lumos Pharma Inc (Director · Feb 16, 2021 – Dec 12, 2024 · Past)
Audit Committee, Compensation Committee · Since at least Dec 3, 2019
David Ramsay
Other companies: Halozyme Therapeutics, Inc. (President, Drug Delivery · Since at least Mar 23, 2026); La Jolla Pharmaceutical Co (Director · Oct 8, 2019 – Aug 22, 2022 · Past)
Director · Since at least Jun 19, 2019
All 47 people
PersonSeat
Evan Levine
Other companies: ProBility Media Corp. (Chief Executive Officer, Director · Nov 8, 2016 – Nov 30, 2018 · Past); Quantrx Biomedical (Director · Feb 6, 2007 – Feb 6, 2007 · Past)
CEO & President, Director · Apr 24, 2006 – Apr 15, 2008 · Past
Nevan Charles Elam
Other companies: Rezolute, Inc. (Chief Executive Officer & Founder · Since at least Jan 31, 2013); Nektar Therapeutics (SVP & Head of Pulmonary Bus · Mar 10, 2006 – Feb 25, 2008 · Past)
Compensation Committee (Chair), Nominating & Governance Committee · Since at least Apr 27, 2017
Ricky Sun
Other companies: Annexon, Inc. (Director · Jul 23, 2020 – Jun 2, 2021 · Past); Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Jun 9, 2021 · Past)
Director · Dec 24, 2019 – Dec 14, 2023 · Past
Robert Martin Emanuele
Other companies: Artelo Biosciences, Inc. (Director · Since at least Jun 21, 2019); Avanir Pharmaceuticals Inc (V P, Business Development · May 25, 2006 – May 25, 2006 · Past)
Senior VP, Development · Apr 27, 2011 – Jan 4, 2016 · Past
Rob Lutz
Other companies: iBio, Inc. (See Remarks · Mar 4, 2021 – Nov 11, 2022 · Past); Strongbridge Biopharma plc (Chief Financial Officer · Sep 3, 2019 – Feb 22, 2021 · Past)
Chief Operating and Financial Officer · Since at least Feb 13, 2023
Badrul A Chowdhury
Other companies: Kineta Inc. (Director · May 12, 2019 – Jun 29, 2020 · Past)
CHIEF MEDICAL OFFICER · Nov 27, 2019 – Dec 14, 2021 · Past
Gregory Gorgas
Other companies: Artelo Biosciences, Inc. (President & Chief Executive Officer · Since at least Jun 21, 2019)
Senior VP, Commercial · Jul 21, 2011 – Jan 4, 2016 · Past
Jack Lief
Other companies: Arena Pharmaceuticals Inc (President and CEO, Director · Dec 30, 2005 – Mar 3, 2015 · Past)
Director · Sep 22, 2006 – Jun 11, 2015 · Past
Joachim PH Schupp
Other companies: Harrow, Inc. (CHIEF MEDICAL OFFICER · Oct 12, 2009 – Apr 1, 2013 · Past)
VP, Medical Affairs · Aug 15, 2006 – Mar 31, 2008 · Past
Lewis Shuster
Other companies: Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 13, 2018 · Past)
Director · Apr 8, 2011 – Jun 11, 2015 · Past
Mark Bagnall
Other companies: Via Pharmaceuticals Inc (Director · Dec 17, 2007 – Dec 17, 2008 · Past)
CFO & Executive Vice President, Director · Jun 2, 2006 – Apr 3, 2008 · Past
Raymond Dennis Pratt
Other companies: Rockwell Medical, Inc. (Chief Development Officer · Jun 14, 2013 – May 3, 2021 · Past)
Chief Medical Officer · Nov 10, 2022 – Dec 12, 2024 · Past
Ali AtayaM.D., MBA, ATSF · Since at least Aug 18, 2025
Anne EricksonChief Business and Corporate Affairs Officer · Since at least Mar 21, 2024
Braden ParkerChief Commercial Officer · Since at least Sep 24, 2024
Brian RobinsonEVP, Global Medical Affairs · Since at least Nov 5, 2026
Bruce TrapnellM.D. · Since at least Oct 21, 2026
Charles LaPreeEVP, Head of Global Regulatory Affairs · Since at least Nov 5, 2026
Cormac McCarthyM.D., Ph.D., FRCPI · Since at least Aug 25, 2026
David L LowranceChief Financial Officer · Since at least Apr 27, 2017
Edwin L ParsleyChief Medical Officer & SVP · Sep 1, 2014 – Jan 20, 2017 · Past
Francesco BonellaM.D., Ph.D · Since at least Sep 29, 2025
Ilaria CampoPh.D. · Since at least Aug 25, 2026
Joan M RobbinsCSO, Sr. VP · Jan 31, 2006 – May 13, 2008 · Past
Kate McCabeChief Legal Officer · Since at least Jul 30, 2026
Kathleen R McCabeChief Legal Officer · Since at least Mar 13, 2025
Maria KokosiM.D. · Since at least Nov 4, 2026
Mark E ErwinSVP, Operations · Oct 20, 2008 – Jan 30, 2009 · Past
Mark Joseph CantwellVP, Research & Development · Feb 28, 2006 – Jan 12, 2007 · Past
Megan CarpenterChief People Officer · Since at least Nov 5, 2026
M Ross JohnsonDirector · Jun 2, 2006 – Dec 21, 2006 · Past
Robert N NevilleChief Executive Officer, Director · Apr 27, 2017 – Dec 20, 2019 · Past
Shana HoodGeneral Counsel & VP · Jan 19, 2016 – Jan 20, 2017 · Past
Sid AdvantEVP, Global Technical Operations · Since at least Nov 5, 2026
Yasmine WasfiChief Medical Officer · Since at least Oct 17, 2025
Yoshikazu InoueM.D., Ph.D. · Since at least Aug 25, 2026
Yuri PikoverDirector · Apr 27, 2017 – Dec 13, 2018 · Past

Open People

Log in to ask 6ix AI your own questions about Savara, Inc.